Enliven Therapeutics, Inc. (NASDAQ:ELVN) Holdings Trimmed by Nicholas Investment Partners LP

Nicholas Investment Partners LP trimmed its position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 9.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 157,635 shares of the company's stock after selling 16,110 shares during the quarter. Nicholas Investment Partners LP owned 0.32% of Enliven Therapeutics worth $3,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Tower Research Capital LLC TRC boosted its holdings in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock worth $36,000 after buying an additional 1,114 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Enliven Therapeutics during the 4th quarter valued at $97,000. BNP Paribas Financial Markets purchased a new position in Enliven Therapeutics in the 4th quarter worth $112,000. ExodusPoint Capital Management LP purchased a new position in Enliven Therapeutics in the 4th quarter worth $200,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Enliven Therapeutics in the fourth quarter valued at about $228,000. 95.08% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 5,000 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $16.07, for a total transaction of $80,350.00. Following the sale, the insider now directly owns 997,688 shares of the company's stock, valued at approximately $16,032,846.16. This represents a 0.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Samuel Kintz sold 12,500 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $20.83, for a total value of $260,375.00. Following the sale, the chief executive officer now directly owns 990,392 shares in the company, valued at approximately $20,629,865.36. This represents a 1.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 76,111 shares of company stock valued at $1,493,145 in the last three months. Corporate insiders own 29.20% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday. Jones Trading reduced their price objective on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research note on Friday. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Enliven Therapeutics presently has an average rating of "Buy" and a consensus price target of $37.25.

Enliven Therapeutics Price Performance

Shares of ELVN traded down $0.56 during mid-day trading on Monday, reaching $16.30. The stock had a trading volume of 126,881 shares, compared to its average volume of 263,203. Enliven Therapeutics, Inc. has a 52-week low of $13.30 and a 52-week high of $30.03. The firm has a market cap of $799.82 million, a price-to-earnings ratio of -8.58 and a beta of 1.07. The business's fifty day moving average is $18.84 and its 200 day moving average is $21.65.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). As a group, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 EPS for the current fiscal year.

Enliven Therapeutics Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.